Myelodysplastic Syndrome and Leukemia
A disease benign years syndrome MYELODYSPLASIQUE (MDS) is known as a serious risk to which it represents people today. Recent studies have shown that MDS is actually a malignant disease, yet can cause leukaemia. Due to is this MYELODYSPLASIQUE syndrome in fact also pre leukemia known as disease.
Much like leukemia, MDS resolves an overproduction of unusual blood cells, which have finally your healthy on equivalents. The cells caused by the disease in question are called mailings and in this window originate from the bone marrow. Dysfunktionalen mailings multiply exceptionally fast data transfer rates and collect in the bone marrow or in the car. These functionless perturb the production of normal blood cells, a reduction in the number of red blood cells, white blood cells and platelets pool caused cells. Therefore people with MDS have weakened anaemia (due to less red cells), immune system (due to less white blood cells) and slow healing experience (due to less platelets).
Many patients with leukemia in developing MDS diagnosed are at risk. For the progress of the MDS block and prevent the emergence leukemia, most patients receive treatment with Decitabine, new medicines, the test currently.
Although most patients with MDS diagnosed to treatment by mild chemotherapy drugs and respond Decitabine you of often experience rechute after you have completed the prescribed course of drugs. MDS has a very recurring character and despite its curability high in the early stages of the disease, it is very difficult to treat in the later stages of the development.
Oncologists have noticed that patients who relapse also meet second treatment less. The exact why reasons most patients with MDS to re treatment responses which are still unknown. However, this problem solve, raw processing time extension. Medical scientists explain that a single long term chemotherapy drugs and Decitabine courses provide better frequently repeated results of shorter treatments. You keep that extending from fresh chemotherapy beyond of the patients with MDS adoption, edge treatment relapse less is likely to drugs and Decitabine. In addition, medical scientists say that patients who have reached the ongoing maintenance of discount must follow treatment in order to prevent the recurrence of the disease.
Recently confirmed tests carried out, the fact that treatments in long-term offer better results than the repeated treatments to overcome MDS. Not only patients who receive short-term experience has failed, but are also more exposed to develop acute leukemia and other serious forms of blood cancer. To avoid this dose low breakthrough can first treatment with Decitabine followed by maintenance treatments the best option for patients with MDS be diagnosed.
[answer]
Leave a Reply
